Biogen shares are trading lower after European experts considering the potential use of the company's Alzheimer's drug, Leqembi, said the drug's ability to slow cognitive decline may not outweigh its risks.
Portfolio Pulse from Benzinga Newsdesk
Biogen shares are trading lower after European experts expressed concerns that the company's Alzheimer's drug, Leqembi, may not provide enough benefits to outweigh its risks.
June 13, 2023 | 5:46 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Biogen's stock price is negatively impacted by European experts' concerns about the benefits of its Alzheimer's drug, Leqembi, compared to its risks.
The article states that Biogen shares are trading lower due to concerns raised by European experts about the company's Alzheimer's drug, Leqembi. These experts believe that the drug's ability to slow cognitive decline may not outweigh its risks, which could negatively impact the stock price in the short term as investors react to this news.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100